Apr 16, 2018 05:58 PM IST | Source: Moneycontrol.com

Cipla Q4 PAT seen up 57.7% YoY to Rs. 322 cr: Edelweiss

Net Sales are expected to increase by 6.2 percent Y-o-Y (down 2.8 percent Q-o-Q) to Rs. 3,805.3 crore, according to Edelweiss.

Moneycontrol News
Cipla-InvaGen/Exelan acquisition | Year: September 2015 | Deal size: USD 550 million Objective: To scale-up US generics business and have manufacturing presence in that market. Results: The InvaGen/Exelan buy has expanded Cipla’s US base, but failed to deliver on the commercial potential of limited competition filings such as generic Renvela and generic Fosrenol. Since the acquisition, Cipla has already taken USD 110 million of impairments on the acquisition, which accounts for nearly 20 percent of the acquisition cost. (Image: Reuters)
Cipla-InvaGen/Exelan acquisition | Year: September 2015 | Deal size: USD 550 million Objective: To scale-up US generics business and have manufacturing presence in that market. Results: The InvaGen/Exelan buy has expanded Cipla’s US base, but failed to deliver on the commercial potential of limited competition filings such as generic Renvela and generic Fosrenol. Since the acquisition, Cipla has already taken USD 110 million of impairments on the acquisition, which accounts for nearly 20 percent of the acquisition cost. (Image: Reuters)
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Edelweiss has come out with its fourth quarter (Jan-March’ 18) earnings estimates for the Pharma sector. The brokerage house expects Cipla to report net profit at Rs. 322 crore up 57.7% year-on-year (down 16% quarter-on-quarter).


Net Sales are expected to increase by 6.2 percent Y-o-Y (down 2.8 percent Q-o-Q) to Rs. 3,805.3 crore, according to Edelweiss.


Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to rise by 30 percent Y-o-Y (down 19.6 percent Q-o-Q) to Rs. 657.9 crore.


Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.